STAT reports from a peptide medicine conference where stem cell entrepreneur Chuck Meeker predicted FDA roundtables before year end. The FDA declined to comment.
Recap by typeshit. Full story at STAT.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Full ACHIEVE-4 results for orforglipron in type 2 diabetes, shown at EASD in Milan and in The Lancet, also report weight loss and lower blood pressure and triglycerides.
CNBC-TV18's Ekta Batra reports the combo beat high-dose tirzepatide alone at 14.8%, but 27% of patients dropped out over side effects. Lilly plans Phase 3 by end of 2026.
Loading…